The thrombopoietin mimetic JNJ-26366821 increases megakaryopoiesis without affecting malignant myeloid proliferation

References

• Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007;109(9):1705–1714.
   PubMed Web of Science ®Google Scholar
• Webert K, Cook RJ, Sigouin CS, et al. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica. 2006;91(11):1530–1537.
   PubMed Web of Science ®Google Scholar
• Neukirchen J, Blum S, Kuendgen A, et al. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. Eur J Haematol. 2009;83(5):477–482.
   PubMed Web of Science ®Google Scholar
• Blumberg N, Heal JM, Phillips GL, et al. Platelets–to transfuse or not to transfuse. Lancet. 2012;380(9850):1287–1289.
   PubMed Web of Science ®Google Scholar
• Comont T, Tavitian S, Bardiaux L, et al. Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy. Leuk Res. 2017;61:62–67.
   PubMed Web of Science ®Google Scholar
• Akahoshi Y, Kanda J, Gomyo A, et al. Risk factors and impact of secondary failure of platelet recovery after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(9):1678–1683.
   PubMed Web of Science ®Google Scholar
• Bolwell B, Pohlman B, Sobecks R, et al. Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant. 2004;33(4):419–423.
   PubMed Web of Science ®Google Scholar
• Bruno B, Gooley T, Sullivan KM, et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7(3):154–162.
   PubMed Web of Science ®Google Scholar
• Kim DH, Sohn SK, Baek JH, et al. Clinical significance of platelet count at day +60 after allogeneic peripheral blood stem cell transplantation. J Korean Med Sci. 2006;21(1):46–51.
   PubMed Web of Science ®Google Scholar
• Shastri A, Verma AK. Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML. Lancet Haematol. 2018;5(1):e6–e7.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Carli G. Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists. Ann Hematol. 2017;96(9):1421–1434.
   PubMed Web of Science ®Google Scholar
• Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014;120(12):1838–1846.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Garcia-Manero G, Moore M, et al. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma. 2013;54(2):321–328.
   PubMed Web of Science ®Google Scholar
• Oliva EN, Alati C, Santini V, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017;4(3):e127–e136.
   PubMed Web of Science ®Google Scholar
• Frey N, Jang JH, Szer J, et al. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. Lancet Haematol. 2019;6(3):e122–e131.
   PubMed Web of Science ®Google Scholar
• Dickinson M, Cherif H, Fenaux P, et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018;132(25):2629–2638.
   PubMed Web of Science ®Google Scholar
• Bussel JB. The new thrombopoietic agenda: impact on leukemias and MDS. Best Pract Res Clin Haematol. 2014;27(3–4):288–292.
   PubMed Web of Science ®Google Scholar
• Santini V. Treatment of low-risk myelodysplastic syndrome: hematopoietic growth factors erythropoietins and thrombopoietins. Semin Hematol. 2012;49(4):295–303.
   PubMed Web of Science ®Google Scholar
• Mittelman M, Platzbecker U, Afanasyev B, et al. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol. 2018;5(1):e34–e43.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Muus P, Kantarjian H, et al. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol. 2017;178(6):906–913.
   PubMed Web of Science ®Google Scholar
• Prica A, Sholzberg M, Buckstein R. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials. Br J Haematol. 2014;167(5):626–638.
   PubMed Web of Science ®Google Scholar
• Dodillet H, Kreuzer KA, Monsef I, et al. Thrombopoietin mimetics for patients with myelodysplastic syndromes. Cochrane Database Syst Rev. 2017;9:CD009883.
   PubMed Web of Science ®Google Scholar
• Knight E, Eichenbaum G, Hillsamer V, et al. Nonclinical safety assessment of a synthetic peptide thrombopoietin agonist: effects on platelets, bone homeostasis, and immunogenicity and the implications for clinical safety monitoring of adverse bone effects. Int J Toxicol. 2011;30(4):385–404.
   PubMed Web of Science ®Google Scholar
• Liem-Moolenaar M, Cerneus D, Molloy CJ, et al. Pharmacodynamics and Pharmacokinetics of the Novel Thrombopoietin Mimetic Peptide RWJ-800088 in Humans. Clin Pharmacol Ther. 2008;84(4):481–487.
   PubMed Web of Science ®Google Scholar
• Ashcraft KA, Choudhury KR, Birer SR, et al. Application of a novel murine ear vein model to evaluate the effects of a vascular radioprotectant on radiation-induced vascular permeability and leukocyte adhesion. Radiat Res. 2018;190(1):12–21.
   PubMed Web of Science ®Google Scholar
• Ashcraft KA, Hannan JL, Eichenbaum G, et al. Clarifying the relative impacts of vascular and nerve injury that culminate in erectile dysfunction in a pilot study using a rat model of prostate irradiation and a thrombopoietin mimetic. Int J Radiat Oncol Biol Phys. 2019;103(5):1212–1220.
   PubMed Web of Science ®Google Scholar
• Langer HF, Stellos K, Steingen C, et al. Platelet derived bFGF mediates vascular integrative mechanisms of mesenchymal stem cells in vitro. J Mol Cell Cardiol. 2009;47(2):315–325.
   PubMed Web of Science ®Google Scholar
• Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 2009;114(18):3899–3908.
   PubMed Web of Science ®Google Scholar
• Langenkamp U, Siegler U, Jorger S, et al. Human acute myeloid leukemia CD34 + CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells. Haematologica. 2009;94(11):1590–1594.
   PubMed Web of Science ®Google Scholar
• Seita J, Weissman IL. Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med. 2010;2(6):640–653.
   PubMed Web of Science ®Google Scholar
• Roth M, Will B, Simkin G, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012;120(2):386–394.
   PubMed Web of Science ®Google Scholar
• Kalota A, Selak MA, Garcia-Cid LA, et al. Eltrombopag modulates reactive oxygen species and decreases acute myeloid leukemia cell survival. PLoS One. 2015;10(4):e0126691.
   PubMed Web of Science ®Google Scholar
• Basood M, Oster HS, Mittelman M. Thrombocytopenia in patients with myelodysplastic syndromes – still an unsolved problem. Mediterr J Hematol Infect Dis. 2018;10(1):e2018046.
   PubMed Web of Science ®Google Scholar
• Gao C, Wang J, Li Y, et al. Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(34):e11860.
   PubMed Web of Science ®Google Scholar
• Li W, Morrone K, Kambhampati S, et al. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies. Leukemia. 2016;30(3):536–544.
   PubMed Web of Science ®Google Scholar
• Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica. 1998;83(4):358–368.
   PubMed Web of Science ®Google Scholar
• Brand A. Immunological complications of blood transfusions. Presse Med. 2016;45(7–8 Pt 2):e313–e324.
   PubMed Web of Science ®Google Scholar
• Desborough M, Estcourt LJ, Doree C, et al. Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev. 2016;22(8):CD010982.
   Google Scholar